Loading
SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Non-small-cell lung cancer and 1 more.
Involved in actively transporting phosphate into cells via Na(+) cotransport.
Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes clinical 0.15, literature 0.96, genetic association 0.48, somatic mutation 0.86, animal model 0.28). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Colorectal Adenocarcinoma, Lung Adenocarcinoma.
In plain words · SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Non-small-cell lung cancer and 1 more.
SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Non-small-cell lung cancer and 1 more.
Involved in actively transporting phosphate into cells via Na(+) cotransport. Location: Apical cell membrane (UniProt).
No product in this corpus aims at SLC34A2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance) and a fusion partner (UniProt records a translocation), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SLC34A2: RNA tissue enriched (lung 710 nTPM); high antibody staining in 4 normal tissues; highest cancer staining endometrial cancer (3 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Colorectal cancer, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O95436; IntOGen SLC34A2; Human Protein Atlas SLC34A2 tissue; Open Targets ENSG00000157765 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Feild J.A. et al, Biochem. Biophys. Res. Commun, 1999, "Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine". Source.
Sources: HGNC HGNC:11020 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95436 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000157765 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.57, lung cancer 0.60 (GraphQL API, CC0)); IntOGen SLC34A2 (driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Involved in actively transporting phosphate into cells via Na(+) cotransport. Location: Apical cell membrane (UniProt). Locus 4p15.2 (HGNC).
RNA: tissue enriched (lung 710 nTPM), detected in many normal tissues.
Medium: Small intestine.
RNA cancer enhanced: Lung Adenocarcinoma 765 pTPM, Thyroid Carcinoma 987 pTPM.
Medium only: liver cancer, lung cancer, pancreatic cancer, urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SLC34A2" OR ABSTRACT:"SLC34A2" OR TITLE:"solute carrier family 34 member 2" OR ABSTRACT:"solute carrier family 34 member 2" OR TITLE:"Sodium-dependent phosphate transport protein 2B" OR ABSTRACT:"Sodium-dependent phosphate transport protein 2B" OR TITLE:"NAPI-3B" OR ABSTRACT:"NAPI-3B" OR TITLE:"NaPi-2b" OR ABSTRACT:"NaPi-2b" OR TITLE:"NPTIIb" OR ABSTRACT:"NPTIIb") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SLC34A2, not a curated reading list.